201 related articles for article (PubMed ID: 25060522)
1. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway.
Lin CY; Chen HJ; Huang CC; Lai LC; Lu TP; Tseng GC; Kuo TT; Kuok QY; Hsu JL; Sung SY; Hung MC; Sher YP
Cancer Res; 2014 Sep; 74(18):5229-43. PubMed ID: 25060522
[TBL] [Abstract][Full Text] [Related]
2. ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis.
Chiu KL; Lin YS; Kuo TT; Lo CC; Huang YK; Chang HF; Chuang EY; Lin CC; Cheng WC; Liu YN; Lai LC; Sher YP
Oncotarget; 2017 Jul; 8(29):47365-47378. PubMed ID: 28537886
[TBL] [Abstract][Full Text] [Related]
3. ADAM9 enhances CDCP1 protein expression by suppressing miR-218 for lung tumor metastasis.
Chiu KL; Kuo TT; Kuok QY; Lin YS; Hua CH; Lin CY; Su PY; Lai LC; Sher YP
Sci Rep; 2015 Nov; 5():16426. PubMed ID: 26553452
[TBL] [Abstract][Full Text] [Related]
4. ADAM9 promotes lung cancer progression through vascular remodeling by VEGFA, ANGPT2, and PLAT.
Lin CY; Cho CF; Bai ST; Liu JP; Kuo TT; Wang LJ; Lin YS; Lin CC; Lai LC; Lu TP; Hsieh CY; Chu CN; Cheng DC; Sher YP
Sci Rep; 2017 Nov; 7(1):15108. PubMed ID: 29118335
[TBL] [Abstract][Full Text] [Related]
5. ADAM9 up-regulates N-cadherin via miR-218 suppression in lung adenocarcinoma cells.
Sher YP; Wang LJ; Chuang LL; Tsai MH; Kuo TT; Huang CC; Chuang EY; Lai LC
PLoS One; 2014; 9(4):e94065. PubMed ID: 24705471
[TBL] [Abstract][Full Text] [Related]
6. The emerging role of the MiR-1272-ADAM9-CDCP1 signaling pathway in the progression of glioma.
Geng F; Lu GF; Luo YJ; Dominguez S; Kong DY; Shen LH; Luo XM; Yang X; Hu M; Lai WS; Jiang ZS; Chen YS
Aging (Albany NY); 2020 Nov; 13(1):894-909. PubMed ID: 33260155
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis.
Shintani Y; Higashiyama S; Ohta M; Hirabayashi H; Yamamoto S; Yoshimasu T; Matsuda H; Matsuura N
Cancer Res; 2004 Jun; 64(12):4190-6. PubMed ID: 15205330
[TBL] [Abstract][Full Text] [Related]
8. ADAM9 expression promotes an aggressive lung adenocarcinoma phenotype.
Kossmann CM; Annereau M; Thomas-Schoemann A; Nicco-Overney C; Chéreau C; Batteux F; Alexandre J; Lemare F
Tumour Biol; 2017 Jul; 39(7):1010428317716077. PubMed ID: 28675123
[TBL] [Abstract][Full Text] [Related]
9. CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis.
Liu H; Ong SE; Badu-Nkansah K; Schindler J; White FM; Hynes RO
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1379-84. PubMed ID: 21220330
[TBL] [Abstract][Full Text] [Related]
10. Suppression of autophagy by CUB domain-containing protein 1 signaling is essential for anchorage-independent survival of lung cancer cells.
Uekita T; Fujii S; Miyazawa Y; Hashiguchi A; Abe H; Sakamoto M; Sakai R
Cancer Sci; 2013 Jul; 104(7):865-70. PubMed ID: 23510015
[TBL] [Abstract][Full Text] [Related]
11. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma.
Uekita T; Jia L; Narisawa-Saito M; Yokota J; Kiyono T; Sakai R
Mol Cell Biol; 2007 Nov; 27(21):7649-60. PubMed ID: 17785447
[TBL] [Abstract][Full Text] [Related]
12. Lung cancer-derived galectin-1 enhances tumorigenic potentiation of tumor-associated dendritic cells by expressing heparin-binding EGF-like growth factor.
Kuo PL; Huang MS; Cheng DE; Hung JY; Yang CJ; Chou SH
J Biol Chem; 2012 Mar; 287(13):9753-9764. PubMed ID: 22291012
[TBL] [Abstract][Full Text] [Related]
13. RNAi-mediated A disintegrin and metalloproteinase 9 gene silencing inhibits the tumor growth of non-small lung cancer in vitro and in vivo.
Chang L; Gong F; Cui Y
Mol Med Rep; 2015 Jul; 12(1):1197-204. PubMed ID: 25778452
[TBL] [Abstract][Full Text] [Related]
14. HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.
Zhang J; Chen N; Qi J; Zhou B; Qiu X
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1441-9. PubMed ID: 24770635
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of microRNA-95-3p suppresses brain metastasis of lung adenocarcinoma through downregulation of cyclin D1.
Hwang SJ; Lee HW; Kim HR; Song HJ; Lee DH; Lee H; Shin CH; Joung JG; Kim DH; Joo KM; Kim HH
Oncotarget; 2015 Aug; 6(24):20434-48. PubMed ID: 25971210
[TBL] [Abstract][Full Text] [Related]
16. RNAi-mediated ADAM9 gene silencing inhibits metastasis of adenoid cystic carcinoma cells.
Xu Q; Liu X; Cai Y; Yu Y; Chen W
Tumour Biol; 2010 Jun; 31(3):217-24. PubMed ID: 20422344
[TBL] [Abstract][Full Text] [Related]
17. Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression.
Lin CC; Huang YK; Cho CF; Lin YS; Lo CC; Kuo TT; Tseng GC; Cheng WC; Chang WC; Hsiao TH; Lai LC; Shih JY; Liu YH; Chao KSC; Hsu JL; Lee PC; Sun X; Hung MC; Sher YP
Theranostics; 2020; 10(24):10925-10939. PubMed ID: 33042262
[No Abstract] [Full Text] [Related]
18. CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation.
Wright HJ; Hou J; Xu B; Cortez M; Potma EO; Tromberg BJ; Razorenova OV
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6556-E6565. PubMed ID: 28739932
[TBL] [Abstract][Full Text] [Related]
19. microRNA-590 suppresses the tumorigenesis and invasiveness of non-small cell lung cancer cells by targeting ADAM9.
Wang FF; Wang S; Xue WH; Cheng JL
Mol Cell Biochem; 2016 Dec; 423(1-2):29-37. PubMed ID: 27770372
[TBL] [Abstract][Full Text] [Related]
20. Identification of theranostic factors for patients developing metastasis after surgery for early-stage lung adenocarcinoma.
Cheng WC; Chang CY; Lo CC; Hsieh CY; Kuo TT; Tseng GC; Wong SC; Chiang SF; Huang KC; Lai LC; Lu TP; Chao KSC; Sher YP
Theranostics; 2021; 11(8):3661-3675. PubMed ID: 33664854
[No Abstract] [Full Text] [Related]
[Next] [New Search]
